1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Inspections of Establishments Performance Dashboards
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Inspections of Establishments Performance Dashboards

 

Subscribe to FDA-TRACK Updates

 

FDA-TRACK: CDER
FDA-TRACK: Biologics
FDA-TRACK: Medical Devices
FDA-TRACK: Animal and Veterinary
FDA-TRACK Home Page

First enacted in 2012 as part of the Food and Drug Administration Safety and Innovation Act (FDASIA), the FDA User Fee Reauthorization Act of 2022, reauthorizes FDA to assess and collect fees for generic drug products from October 2023 through September 2027. GDUFA is designed to speed the delivery of safe and effective generic drugs to the public and improve upon the predictability of the review process.

Section 705 of the Food and Drug Administration Safety and Innovation Act (FDASIA) requires FDA to publish annual reports on inspections of establishments registered under section 510 of the FD&C Act (the Report). The Inspections of Establishments Performance Dashboards provide a concise, interactive, and visual presentation of data presented in the Report. The Inspections of Establishments Performance Dashboards are not intended to replace the Report and are to be used as a supplemental tool for viewing the data. 

 

Data Dashboards to be added.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.
Back to Top